問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

China Medical University Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

鍾智淵
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鍾智淵

List

55Cases

2024-03-01 - 2026-03-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2014-01-01 - 2021-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2010-11-01 - 2019-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-07-30 - 2025-05-13

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-07-03 - 2020-08-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated7Sites

林振源
China Medical University Hospital-Taipei

未分科

2016-04-04 - 2024-05-12

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2013-03-01 - 2016-10-31

Phase III

A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPLATIN (mFOLFOX6) IN PATIENTS WITH METASTATIC HER2-NEGATIVE, MET-POSITIVE GASTROESOPHAGEAL CANCER

  • Condition/Disease

    METASTATIC HER2-NEGATIVE, MET-POSITIVE GASTROESOPHAGEAL CANCER

  • Test Drug

    ONARTUZUMAB (MetMAb)

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2012-06-30 - 2019-06-30

Phase III

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment with CHOP-based Chemotherapy

  • Condition/Disease

    Previously Undiagnosed Peripheral T-cell Lymphoma

  • Test Drug

    Pralatrexate

Participate Sites
8Sites

Terminated8Sites

2013-09-01 - 2017-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB